SUBSCRIBE
SUBSCRIBE
News   Policy

Neurocrine Biosciences, Inc. Delays Indiplon Application To Summer 2008

November 3, 2006 | 
1 min read

Nov 2 (Reuters) - Neurocrine Biosciences Inc. (NBIX.O: Quote, Profile, Research) on Thursday delayed the re-submission for approval of its experimental sleep drug indiplon to summer 2008.

>>> Discuss This Story

Regulatory
MORE ON THIS TOPIC
Weigh scales on pink background, top view with space for text. Overweight concept
Obesity
UK Pharmacies Regulator Wants Tighter Checks on Weight Loss Injections
February 4, 2025
 · 
2 min read
 · 
Tristan Manalac
Government
Trump’s Tariffs Threaten Big Pharma With Higher Costs and Slimmer Margins
February 3, 2025
 · 
3 min read
 · 
Tristan Manalac
A scientist with pill bottles in front of FDA headquarters
Regulatory
FDA Action Alert: GSK, Indivior, SpringWorks, More
February 3, 2025
 · 
5 min read
 · 
Tristan Manalac
Profile view, and Mental Illness
Approvals
Axsome’s Migraine Medicine Clears FDA Bar
January 31, 2025
 · 
2 min read
 · 
Tristan Manalac